Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Pharming   /   Week 12 - Release Annual Report 2014

Aandeel Pharming Group AEX:PHARM.NL, NL0010391025

Laatste koers (eur) Verschil Volume
0,893   +0,020   (+2,23%) Dagrange 0,884 - 0,901 3.728.995   Gem. (3M) 6,5M

Week 12 - Release Annual Report 2014

Volgen
634 Posts
Pagina: «« 1 ... 19 20 21 22 23 ... 32 »» | Laatste | Omlaag ↓
  3. wesmail 19 maart 2015 08:23
    As a result of our achievements in 2014 and the ongoing development projects, we look forward with confidence to an exciting 2015, with potentially significant value-inflexion points and again increasing
    Ruconest sales, both from our partners and as a result of our own commercialisation activitie
  8. MSN 19 maart 2015 08:33
    Sorry als het een beetje lastig te lezen is. Doe dit vanaf mn telefoon. Samengevat zien de cijfers er goed uit. Even de rest doorlezen :)

    FINANCIAL
    ? Revenues increased to €21.2 million (2013: €6.8 million).
    ? Mainly as a result of higher license fees, including the receipt of a US$20.0 million (€16.0 million) milestone
    from US partner Salix, while 2013 included a US$5.0 million (€3.8 million) milestone from Santarus (now
    Salix Pharmaceuticals, Inc.).
    ? Product sales increased to €3.0 million (2013: €0.9 million) as a result of increased sales in the EU and initial
    sales orders in the US of €0.3 million.
    ? Operating result improved to an operating profit of €2.9 million in 2014 from a loss of €6.9 million in 2013.
    ? Net loss decreased from €15.1 million to €5.8 million in 2014.
    ? The equity position increased to €29.8 million at year-end 2014 (2013: €5.0 million), mainly as a result of the
    receipt of the US$20.0 million milestone, a private equity placement of net €14.0 million and the exercise of
    warrants.
    ? In preparation of further commercialisation of Ruconest, the inventories of Ruconest, including work in progress
    and skimmed milk, increased to €13.4 million at year-end 2014 (2013: €4.8 million).
    ? The cash position, including restricted cash, improved to €34.4 million at year-end 2014 (2013: €19.2 million),
    mainly as a result of the receipt of the milestone payment from Salix, the private equity placement of net €14.0
    million and the exercise of warrants of €4.6 million.
  10. twopence 19 maart 2015 08:38
    [quote alias=tonneke id=8352765 date=201503190832]
    In korte tijd 3 nieuwe aangenomen, als ze maar niet gaan klaverjasse :-)
    [/quote

    Is te hopen van niet zeg. Lang genoeg moeten wachten op verbeterde resultaten. Nu alleen nog wachten op winst van bedrijf dan kunnen wij met z'n allen lekker rustig slapen.
  18. patrick 22 19 maart 2015 08:52
    The main corporate objectives for 2015 for the Board of Management can be summarised as follows:
    ? Increase the value of the Ruconest franchise through support of our existing partners and through geographical
    expansion by securing new partnerships;
    ? Build the C1 Inhibitor franchise by progressing the development of C1 inhibitor in indications beyond acute HAE
    attacks;
    ? Develop the Factor VIII programme according to plan;
    ? Leverage the embedded value of the transgenic technology platform by prioritisation and development of the new
    products leads according to the development plan;
    ? Operate within agreed budgets at the department and company level;
    ? Create a basis for long-term sustainability by broadening the portfolio with new projects, through a rational
    process of commercially led asset evaluations;
    ? Improve the Company’s visibility amongst investors and other market participants (both buy- and sell-side
    analysts and financial press and trade press journalists).
  19. [verwijderd] 19 maart 2015 08:55
    Betreft acute pancreatitis;
    "Santarus began exploring clinical and regulatory strategies to evaluate Ruconest for the treatment of AP. This included discussions with FDA on a pre-IND briefing package for a Phase II clinical study. Salix is now further evaluating the opportunity in AP and will carry on the next steps in development work for this indication."

    Vaag nog steeds....
634 Posts
Pagina: «« 1 ... 19 20 21 22 23 ... 32 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium

Update: Gedurfde overnamezet van Pharming

Het laatste advies leest u als abonnee van IEX Premium

Inloggen Word Abonnee

Pharming Nieuws

  1. CEO: Pharming koopt met KL1333 van Abliva goede kans op blockbuster (video)
  2. RBC verhoogt koersdoel Pharming fors
  3. Afwachtend begin van Super Central Bank-week en we hebben een beursganger
  4. CEO De Vries: Pharming dicht bij overname van nieuwe blockbuster
  5. Pharming brengt bod op Abliva AB uit
  6. Moeizame week voor financials
  7. Weekoverzicht: vastgoed uit de gratie, winst voor automotive en chipaandelen
  8. Fundlogic verkleint belang in Pharming
  9. Fundlogic meldt belang in Pharming
  10. Jefferies: positieve studiedata Pharming vergroten doelgroep Joenja